Home » Imdelltra (Tarlatamab-dlle)
Buy Imdelltra in India — Price & Availability
Imdelltra (tarlatamab-dlle) is a DLL3-directed CD3 T-cell-engaging bispecific antibody given as an intravenous infusion to treat extensive-stage small cell lung cancer (ES-SCLC) that has progressed on or after platinum-based chemotherapy. It is not commercially marketed in India, but can be legally imported on a valid prescription through the Named Patient Program. Indian Pharma Network sources it from licensed US/EU manufacturers and qualified pharmaceutical supply channels with full cold-chain handling.
Looking to buy Imdelltra in India? Imdelltra (tarlatamab-dlle) is a prescription cancer medicine that is not yet commercially marketed in India, but can be legally accessed through the Named Patient Program (NPP).
- Brand name: Imdelltra®
Generic (API): Tarlatamab-dlle - Strength & form: Lyophilised powder for reconstitution, single-dose vials (1 mg and 10 mg) for IV infusion
- Route: Intravenous (IV) infusion
- Drug class: DLL3-directed CD3 bispecific T-cell engager (BiTE®)
- Manufacturer: Amgen Inc.
- Availability in India: Via Named Patient import (not locally marketed)
- Prescription: Required — oncologist supervised
Medically reviewed for accuracy by the Indian Pharma Network (IPN) clinical content team.
Last updated: 2 July 2026 · For informational use; not a substitute for advice from your oncologist.
What is Imdelltra used for?
Imdelltra (tarlatamab-dlle) is a bispecific T-cell engager that binds DLL3 (delta-like ligand 3), a protein found on small cell lung cancer cells, and CD3 on T cells at the same time, bringing the patient’s own T cells into contact with the cancer cells so the T cells can destroy them.
It is approved for adults with:
- Extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
Imdelltra was the first T-cell engager therapy approved for this setting. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.
Recommended dosage:
Imdelltra is given as an intravenous infusion on a step-up dosing schedule to reduce the risk of cytokine release syndrome (CRS):
- 1 mg on Cycle 1, Day 1, followed by 10 mg on Day 8, Day 15, and every 2 weeks thereafter, until disease progression or unacceptable toxicity.
- Patients are well hydrated before infusion, given concomitant medications around Cycle 1 doses to reduce CRS, and monitored in an appropriate healthcare setting (with monitoring for a period after the first two doses, accompanied by a caregiver).
- Complete blood count, liver enzymes, and bilirubin are checked before doses per the schedule in the prescribing information.
The treating oncologist always determines the exact dosing and monitoring plan. Imdelltra must be given only as an IV infusion.
Warnings, precautions, and side effects
Boxed warning — cytokine release syndrome (CRS) and neurologic toxicity, including ICANS: serious or life-threatening CRS and neurologic toxicity (including immune effector cell-associated neurotoxicity syndrome, ICANS) can occur. Treatment is started with the step-up dosing schedule to reduce incidence and severity, and is withheld until the reaction resolves or permanently discontinued based on severity.
- Cytopenias: Imdelltra may reduce blood cell counts, including white blood cells and red blood cells. Regular blood tests help monitor treatment, and any unusual fatigue, bruising, or infection should be reported promptly.
- Infections: Serious infections may occur during Imdelltra treatment. Contact your healthcare provider immediately if you develop fever, chills, cough, sore throat, or any signs of infection requiring prompt medical evaluation.
- Hepatotoxicity: Imdelltra may affect liver function. Your doctor will monitor liver enzymes and bilirubin through regular blood tests during treatment to detect and manage potential liver-related side effects early.
- Hypersensitivity: Allergic or infusion-related reactions may occur during or shortly after Imdelltra infusion. Inform your healthcare team immediately if you experience rash, breathing difficulty, dizziness, or swelling.
- Embryo-fetal toxicity: Imdelltra may harm an unborn baby. Women of childbearing potential should use effective contraception during treatment and discuss pregnancy or breastfeeding plans with their healthcare provider.
Common side effects: The most common side effects (> 20%) include cytokine release syndrome, fatigue, fever (pyrexia), altered taste (dysgeusia), decreased appetite, musculoskeletal pain, constipation, anaemia, and nausea. This is not a complete list — refer to the full prescribing information and your oncologist.
Patients in India can legally access Imdelltra through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:
- Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
- Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
- Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
- Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
- Cold-chain import & delivery — Imdelltra is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.
Documents required to import Imdelltra:
- A valid prescription from a qualified oncologist
- The patient’s diagnostic reports
- Government-issued patient ID proof
- An import permit, where applicable
Because Imdelltra is not sold on the open market in India, there is no fixed MRP. The Imdelltra cost in India depends on a few factors at the time of import:
- The number of vials required across the step-up dosing schedule and subsequent every-2-week doses.
- The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
- Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.
Get a transparent quote: We provide a written quotation covering Imdelltra cost, logistics, and delivery timeline once a valid prescription is shared. Request your Imdelltra quote →
Imdelltra is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid prescription, in line with applicable regulations.
Indian Pharma Network sources Imdelltra from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Imdelltra vials require cold-chain handling: stored refrigerated at 2 °C–8 °C in the original carton, protected from light, and not frozen or shaken. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.
Detail | Information |
Storage | Refrigerate at 2 °C to 8 °C in the original carton; protect from light; do not freeze or shake |
Sourcing regions | USA, Europe, Canada, China, Japan, Singapore, Australia |
Delivery | To the patient’s address or treating hospital, under cold-chain logistics |
Order confirmation | After verification of a valid prescription and import permit (where applicable) |
Is Imdelltra available in India?
Imdelltra (tarlatamab-dlle injections) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, Imdelltra is not commercially marketed in India.
However, patients in India can legally access Imdelltra through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.
Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:
- Availability of Imdelltra in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
- Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
- Imdelltra price in India under the NPP route
- Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
- Ensuring full transparency throughout the process
Imdelltra can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.
Regulatory approval status
Imdelltra first received US FDA accelerated approval on 16 May 2024 for extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy, and was granted traditional (full) approval on 19 November 2025 based on the confirmatory DeLLphi-304 trial. It is also progressing through approvals in other markets. As of the current publicly available information, Imdelltra is not commercially marketed in India, which is why the Named Patient route is used.
How does Imdelltra Import in India work?
Imdelltra Import in India can be done through the Named Patient Program (NPP). This means the medicine can be imported on behalf of the patient with a valid doctor’s prescription. Indian Pharma Network (IPN) helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.
How can I buy Imdelltra in India?
Imdelltra is not commercially marketed in India, but it can be legally accessed through the Named Patient Program. With a valid oncologist’s prescription, diagnostic reports, and a government-issued patient ID, Indian Pharma Network facilitates compliant import in the patient’s name.
What is the price of Imdelltra in India?
Imdelltra is not sold on the open market in India, so the cost depends on sourcing, the number of vials required across the schedule, logistics, and applicable duties at the time of import. A transparent, patient-specific quote is provided once the prescription is verified.
What is Imdelltra used for?
It treats adults with extensive-stage small cell lung cancer that has progressed on or after platinum-based chemotherapy
Who is a reliable Imdelltra supplier in India?
Indian Pharma Network (IPN) is a trusted Imdelltra supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.
Who manufactures Imdelltra?
Imdelltra is manufactured by Amgen. It was the first DLL3-targeting T-cell engager approved for small cell lung cancer.
What is the dosage form and strength of Imdelltra?
Imdelltra is supplied as a lyophilised powder in single-dose vials (1 mg and 10 mg), reconstituted and given by IV infusion. Dosing is 1 mg on Cycle 1 Day 1, then 10 mg on Days 8, 15, and every 2 weeks.
Who is an authorized Imdelltra importer in India?
Indian Pharma Network (IPN) acts as a Imdelltra importer in India. We help with Named Patient Import processes, regulatory documentation, and compliant procurement from leading international manufacturers for patients who need this therapy.
How is Imdelltra stored and delivered?
Imdelltra vials are stored refrigerated at 2 °C to 8 °C in the original carton, protected from light and not frozen, and shipped under validated cold-chain conditions to the patient or treating hospital.
Request Imdelltra price & availability:
Speak with our patient support team for Imdelltra price, availability, quote and guidance on the Named Patient import process. We respond within 24 hours on business days.
- Call: +91-96548 60915
- WhatsApp: +91-98104 69557
- Toll-free: 1800-1200-365
- Email: info@indianpharmanetwork.in
References & sources:
- Imdelltra (tarlatamab-dlle) US Prescribing Information, Amgen Inc.
- US Food & Drug Administration — Imdelltra approval history (accelerated approval 16 May 2024; traditional approval 19 November 2025).
- Imdelltra (tarlatamab-dlle) – Medication Guide
- Imdelltra (tarlatamab-dlle injection) – DailyMed
- Amgen press materials and NCCN guidance for small cell lung cancer.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
Imdelltra® (tarlatamab-dlle for injection) is a prescription anticancer medicine and should only be used under the supervision of a qualified healthcare professional. Indian Pharma Network is a pharmaceutical trading entity that facilitates access to medicines through legally permissible channels, such as Named Patient import, strictly against valid prescriptions. All trademarks and brand names remain the property of their respective owners (Imdelltra® is a registered trademark of Amgen Inc). This page is for informational purposes and does not constitute medical advice. Product availability, import requirements, and pricing vary by country-specific regulations.